Cara Therapeutics (FRA:69C0) Ending Cash Position : €36.20 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Ending Cash Position?

Cara Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 was €36.20 Mil.

Cara Therapeutics's quarterly Ending Cash Position declined from Jun. 2024 (€47.14 Mil) to Sep. 2024 (€34.74 Mil) but then increased from Sep. 2024 (€34.74 Mil) to Dec. 2024 (€36.20 Mil).

Cara Therapeutics's annual Ending Cash Position declined from Dec. 2022 (€60.56 Mil) to Dec. 2023 (€49.23 Mil) and declined from Dec. 2023 (€49.23 Mil) to Dec. 2024 (€36.20 Mil).

Cara Therapeutics Ending Cash Position Historical Data

The historical data trend for Cara Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Ending Cash Position Chart

Cara Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

26.38

12.27

60.56

49.23

36.20

Cara Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															49.23	44.62	47.14	34.74	36.20

Cara Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cara Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	51.267	+	-15.07
	=	36.20

Cara Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	36.825	+	-0.628
	=	36.20

Cara Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Cara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (FRA:69C0) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

CARA:USA 0HTC:UK

Address

400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901

Website

https://www.caratherapeutics.com

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Cara Therapeutics Headlines

No Headlines